Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rotating hinge expandable prostheses may have a higher risk of medial tibial plateau deformity compared to constrained hinged expandable prostheses following reconstruction of distal femur in children with primary bone tumors.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie·2026
Same author

Depth of the Dorsalis Pedis Artery Distal to the First and Second Tarsometatarsal Joints: A Cadaveric Anatomical Study.

Foot & ankle orthopaedics·2026
Same author

Complications, reoperations, and revisions after surgical treatment of humeral metastases with modular prosthesis, intramedullary nailing or plate fixation: a retrospective analysis.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie·2026
Same author

Pain-Related Impairment and Talar Tilt as Predictors of Surgical Decision Making in Advanced Varus Ankle Osteoarthritis.

Foot & ankle orthopaedics·2026
Same author

Can We Develop a Web-based Nomogram That Could Predict the Risk of Local Recurrence After Treatment for Giant Cell Tumor of Bone of the Extremities by Curettage?

Clinical orthopaedics and related research·2026
Same author

Acupuncture vs usual care for chronic low back pain: a systematic review and meta-analysis of immediate and intermediate effects.

SICOT-J·2026

Related Experiment Video

Updated: Jun 8, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

221

Prognostic factors for mesenchymal chondrosarcoma.

Tomoya Masunaga1, Shinji Tsukamoto1, Kanya Honoki1

  • 1Department of Orthopaedic Surgery, Nara Medical University, 840, Shijo-cho, Kashihara-city, Nara 634-8521, Japan.

SICOT-J
|November 8, 2024
PubMed
Summary
This summary is machine-generated.

Mesenchymal chondrosarcoma (MCS) with distant metastases has a poor prognosis. Wide surgical resection is crucial for localized MCS, but adjuvant therapies require further investigation due to limited patient numbers.

Keywords:
AdjuvantChemotherapyMesenchymal chondrosarcomaRadiotherapySurgery

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K

Related Experiment Videos

Last Updated: Jun 8, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

221
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K

Area of Science:

  • Orthopedic Oncology
  • Surgical Pathology
  • Cancer Research

Background:

  • Mesenchymal chondrosarcoma (MCS) is a high-grade, primitive mesenchymal tumor with a poor prognosis.
  • Current treatment for localized MCS relies on wide resection, with ongoing debate about adjuvant therapies.

Purpose of the Study:

  • To investigate prognostic factors in MCS.
  • To evaluate the efficacy of adjuvant chemotherapy and radiotherapy for localized MCS.

Main Methods:

  • Retrospective analysis of 80 patients diagnosed with MCS between 2006 and 2022.
  • Data sourced from the Japanese National Bone and Soft Tissue Tumor Registry database.

Main Results:

  • Distant metastases at presentation significantly correlated with shorter survival (5-year DSS 19.9% vs. 79.8%).
  • In patients without distant metastasis, R1/R2 surgical margins were risk factors for local recurrence and unfavorable disease-specific survival.
  • No significant correlation was found between adjuvant radiotherapy or chemotherapy and local recurrence or disease-specific survival.

Conclusions:

  • Distant metastases at presentation indicate a poor prognosis for MCS patients.
  • Wide surgical resection is vital for localized MCS management.
  • The efficacy of adjuvant radiotherapy and chemotherapy in MCS remains undetermined due to small sample sizes.